In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Falsified Medicines Directive: end of transition period and beginning of monitoring activities

Falsified Medicines Directive: end of transition period and beginning of monitoring activities

by In2Pharma | Nov 4, 2019 | News

Belgium From 9 February  2019, all prescription and reimbursable medicines on the market must bear safety features. At each link in the distribution chain, the safety features must be checked so that the authenticity of the medicine upon delivery can be guaranteed....

Recent Posts

  • Update instructions for distribution of DHPC in Luxembourg
  • Diploma for the Responsible Person for Information and Publicity (RIP)
  • Update Procedure for MA applications in Luxembourg
  • Labeling Medicinal products
  • New clarification about Day 0 in local literature search published by EMA

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België